Trials Offered by a Specific Doctor

HERBERT IRVING COMPREHENSIVE CANCER CENTER
Investigator
Naiyer Rizvi, MD
Email
nar2144@columbia.edu

Dr. Rizvi is the director of thoracic oncology and director of immunotherapeutics for the division of Hematology and Oncology at Columbia University Medical Center.

He also holds the Price Chair in Clinical Translational Research.

He is an internationally recognized leader in the treatment of lung cancer and immunotherapy drug development. Prior to joining Columbia University Medical Center, his clinical research at Memorial Sloan Kettering Cancer played a significant role in the FDA approval path of a new class of immunotherapies, called immune checkpoint inhibitors, for melanoma and lung cancer.

His research focus is studying mechanisms of sensitivity and resistance to immunotherapy. Through genetic testing of tumors, he has been able to improve the understanding of why immune checkpoint inhibitors work in certain patients. This work has been partially supported by Stand Up To Cancer -- Cancer Research Institute Immunology funding.

In his research, he also is studying why certain cancers do not respond to immune checkpoint inhibitors, so we can find better ways to harness the immune system to attack cancer cells. He oversees phase 1 immunotherapy research in solid tumors at Columbia University Medical Center and is conducting key clinical studies of novel immunotherapy drugs and immunotherapy combinations to help more patients in the fight against cancer.


Clinical Studies Managed By Dr. Rizvi:
More InfoTitleSponsorIRB Number
DetailsStudy for patients with advanced Non-small Cell Lung Cancer using study drug MEDI4736MedImmuneAAAP0151
DetailsA study for patients with incurable cancers using study drug CPI-444Corvus Pharmaceuticals, Inc.AAAQ6651
Details[CLOSED] A study for patients with advanced solid tumors using study drug MEDI1873MedImmuneAAAQ7429
DetailsA study for patients with advanced solid tumors using study drug MEDI0562MedImmuneAAAQ7663
DetailsA study for patients with advanced cancers using study drugs PF-04518600 and PF-05082566PfizerAAAQ8228